为牛皮选择系统性药物
Christina Kontzias1, Rithi Chandy1, Steven R Feldman1,2,3
1Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
The Annals of pharmacotherapy
|June 21, 2023
概括
选择最好的中度至重度牛皮治疗方法需要平衡疗效,安全性,患者需求和成本. 没有任何一种药物是优越的;选择范围从快速起作用的干白素 (IL) -17抑制剂到较少的注射和光疗.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 中度至重度的牛皮治疗决策是复杂的.
- 目前的治疗领域包括生物药物,光疗和系统性药物.
- 没有一种单一的治疗选择是普遍最佳的,需要个性化的方法.
研究的目的:
- 审查和比较当前适度至重症牛皮的治疗选择.
- 突出影响治疗选择的因素,包括疗效,安全性,患者偏好,并发症和成本.
- 引导皮肤科医生和患者选择适当的牛皮管理策略.
主要方法:
- 对现有的牛皮治疗指南和临床试验数据的文献综述.
- 对药物的疗效,安全性,服用时间表和成本效益进行比较分析.
- 考虑患者特异性因素,如坚持和并发症.
主要成果:
- 干白素 (IL) - 17 抑制剂提供了快速的症状缓解.
- 生物药物如瑞桑基祖马布,乌斯特基努马布和蒂尔德拉基祖马布提供了一个方便的3个月注射时间表.
- 光疗对于那些避免全身治疗或担心成本的患者来说是一个可行的选择.
- 因fliximab 和 tildrakizumab 可能会改善由于在办公室的管理.
结论:
- 对中度至重度的牛皮的治疗选择需要个性化的方法.
- 皮肤科医生在教育患者了解各种治疗方案方面发挥着至关重要的作用.
- 优化牛皮的管理包括调整治疗特征与个体患者的需求和偏好.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
158
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
158
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
221
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
221
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
01:19Antiasthma Drugs: Leukotriene Modifiers
372
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
372
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
202
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
202
01:26Psychosis: Goals of Pharmacotherapy
172
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
172